Power partnership oncology at MD Anderson expands access to expert cancer care, research, and clinical trials across seven U.S. health systems.
Two dose regimes of golidocitinib combined with CHOP have been explored for the treatment of newly diagnosed PTCL. Both demonstrated promising antitumor activities and a manageable safety profiles.
The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, ...
Ernexa is advancing a best-in-class approach using synthetic, allogeneic iMSCs to provide a scalable, off-the-shelf treatment without needing patient-specific cell harvesting. The Company continues to ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical ...
The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...
Presentation Title: The ADELA study: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA)+ Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2-Advanced Breast Cancer ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...
Investing.com -- CytoMed Therapeutics Limited (NASDAQ:GDTC) stock surged 9.6% on Monday after the company announced a partnership with Universiti Malaya Medical Centre to establish a first-in-human ...
At ASH 2025, researchers reported on 3-year efficacy and safety of lisocabtagene maraleucel in follicular lymphoma patients being treated in the third-line setting or later.
Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback